Relay Therapeutics Inc (NASDAQ:RLAY) — Market Cap & Net Worth
Market Cap & Net Worth: Relay Therapeutics Inc (RLAY)
Relay Therapeutics Inc (NASDAQ:RLAY) has a market capitalization of $2.95 Billion ($2.95 Billion) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5082 globally and #1662 in its home market, demonstrating a 10.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Relay Therapeutics Inc's stock price $14.96 by its total outstanding shares 217940332 (217.94 Million). Review how much debt does Relay Therapeutics Inc carry to assess the company's total debt and financial obligations.
Relay Therapeutics Inc Market Cap History: 2020 to 2026
Relay Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $9.06 Billion to $3.26 Billion (-13.40% CAGR).
Index Memberships
Relay Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.12% | #120 of 976 |
|
NASDAQ Composite
IXIC
|
$41.39 Trillion | 0.01% | #564 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.17% | #76 of 263 |
Weight: Relay Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Relay Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Relay Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
120.08x
Relay Therapeutics Inc's market cap is 120.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $9.06 Billion | $82.65 Million | -$52.41 Million | 109.58x | N/A |
| 2021 | $6.69 Billion | $3.03 Million | -$363.87 Million | 2209.62x | N/A |
| 2022 | $3.26 Billion | $1.38 Million | -$290.51 Million | 2357.73x | N/A |
| 2023 | $2.40 Billion | $25.55 Million | -$341.97 Million | 93.93x | N/A |
| 2024 | $897.91 Million | $10.01 Million | -$337.71 Million | 89.73x | N/A |
| 2025 | $1.84 Billion | $15.36 Million | -$276.48 Million | 120.08x | N/A |
Competitor Companies of RLAY by Market Capitalization
Companies near Relay Therapeutics Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Relay Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
Relay Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Relay Therapeutics Inc's market cap moved from $9.06 Billion to $ 3.26 Billion, with a yearly change of -13.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.26 Billion | +76.83% |
| 2025 | $1.84 Billion | +105.34% |
| 2024 | $897.91 Million | -62.58% |
| 2023 | $2.40 Billion | -26.31% |
| 2022 | $3.26 Billion | -51.35% |
| 2021 | $6.69 Billion | -26.11% |
| 2020 | $9.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Relay Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.95 Billion USD |
| MoneyControl | $2.95 Billion USD |
| MarketWatch | $2.95 Billion USD |
| marketcap.company | $2.95 Billion USD |
| Reuters | $2.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more